Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 5, 2024

Primary Completion Date

February 1, 2026

Study Completion Date

January 31, 2027

Conditions

Lupus NephritisANCA Associated Vasculitis

Interventions

DRUG

PRG-1801 （CAR-T against BCMA）

Patients with refractory LN and ANCA-associated vasculitis will be treated with PRG-1801

Trial Locations (1)

RECRUITING

Tongji Hospital, Wuhan

All Listed Sponsors

collaborator

Shenzhen Pregene Biopharma Co., Ltd.

INDUSTRY

lead

Lingli Dong

OTHER